Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles
Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome …

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by
the absence of functional enzymes that contribute to the degradation of glycosaminoglycans …

The aim of this review is to summarize the evidence on efficacy, effectiveness and safety of
intravenous enzyme replacement therapy (ERT) available for mucopolysaccharidoses …

Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive inherited disease,
caused by deficiency of the enzyme α-L-iduronidase, resulting in accumulation of the …

The mucopolysaccharidoses (MPS), a group of rare genetic disorders caused by defects in
glycosaminoglycan (GAG) catabolism, are progressive, multi-systemic diseases with a high …

Mucopolysaccharidosis type I (MPS I) is a lysosomal disease, caused by a deficiency of the
enzyme alpha-L-iduronidase (IDUA). IDUA catalyzes the degradation of the …

This paper provides a detailed overview and discussion of anaesthesia in patients with
mucopolysaccharidosis (MPS), the evaluation of risk factors in these patients and their …

Lysosomal storage disorders (LSD) comprise a group of diseases caused by a deficiency of
lysosomal enzymes, membrane transporters or other proteins involved in lysosomal biology …

Mucopolysaccharidosis type I (MPS I) is caused by the deficiency of α-l-iduronidase, leading
to the storage of dermatan and heparan sulfate. There is a broad phenotypical spectrum with …

Mucopolysaccharidosis (MPS) type I and II are two closely related lysosomal storage
diseases associated with disrupted glycosaminoglycan catabolism. In MPS II, the first step of …